Corrigendum to "The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017" [Eur J Canc 145 (2021) 11-18]
Eur J Cancer
.
2021 Jul:152:259-261.
doi: 10.1016/j.ejca.2021.04.018.
Epub 2021 May 11.
Authors
Marc A Rodwin
1
,
Julien Mancini
2
,
Ségolène Duran
3
,
Anne-Céline Jalbert
4
,
Patrice Viens
5
,
Dominique Maraninchi
6
,
Anthony Gonçalves
7
,
Patricia Marino
8
Affiliations
1
Law School, Suffolk University, Boston, MA, 02140, USA.
2
Aix-Marseille Univ, APHM, INSERM, IRD, SESSTIM, Hop Timone, BioSTIC, Marseille, France.
3
Department of Clinical Research and Innovation, Institut Paoli Calmettes, Marseille, France.
4
Hospital Center of Draguignan, Draguignan, France.
5
Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.
6
Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.
7
Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Univ, Inserm, CNRS, CRCM, Marseille, France.
8
Institut Paoli Calmettes, SESSTIM UMR1252, Aix Marseille Univ, INSERM, IRD, Marseille, France. Electronic address: patricia.marino@inserm.fr.
PMID:
33994018
DOI:
10.1016/j.ejca.2021.04.018
No abstract available
Publication types
Published Erratum